Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06563323 · ClinicalTrials.gov registry record · Phase 2
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
A Phase 2 study of Wound Heal and Skin Diseases, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT06563323: Recruiting Phase 2 study of Wound Heal and Skin Diseases, sponsored by Oregon Health and Science University.
NCT06563323 is a Phase 2 study of Wound Heal and Skin Diseases that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 17 participants, below the 119-participant average among 23 other Wound Heal trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06563323, a Phase 2 study of Wound Heal and Skin Diseases, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)
Primary Outcome
Defined as the proportion of patients with complete re-epithelization, defined as a100% re-epithelialization without any drainage of the target ulcer at week 32.
Conditions Studied
Interventions
- DRUG Guselkumab
Study Locations (2)
Ohio
- Ohio State Dermatology - Columbus
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2027-08-13 |
| Phase | Phase 2 |
What NCT06563323 shows while recruiting
NCT06563323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 119-participant average among 23 other Wound Heal trials with a reported enrollment target (86% lower).
The record links to 5 conditions, with Wound Heal appearing as the primary indexed condition, and to 1 intervention - of which Guselkumab is the first listed.
NCT06563323 reports a single indexed study location in Ohio, Oregon.
Frequently Asked Questions
What is clinical trial NCT06563323 about?
NCT06563323 is a clinical study titled "Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)". A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)
What is the current status of trial NCT06563323?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2025-02-01. Estimated completion is 2027-08-13.
What conditions does trial NCT06563323 study?
This clinical trial studies the following conditions: Wound Heal, Skin Diseases, Skin Ulcer, Pyoderma Gangrenosum, Pyoderma.
What interventions are being tested in trial NCT06563323?
The interventions under investigation include: Guselkumab (DRUG).
Who is sponsoring clinical trial NCT06563323?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06563323 being conducted?
This trial has 2 study locations across Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wound Heal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06563323's enrollment target sits among peer trials
17 22nd of 23 higher than 2 of 23 other Wound Heal trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Wound Heal trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
4-aminopyridine for Skin Wound Healing
RECRUITING · Phase 2
-
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds
COMPLETED · Phase 2
-
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
COMPLETED · Phase 2
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Tissue Repair Gel in Venous Leg Ulcers in AU/US
RECRUITING · Phase 3
-
Dermabrasion in Mohs: Split-Scar Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI